Influence of intravenous alteplase on endovascular treatment decision-making in acute ischemic stroke due to primary medium-vessel occlusion: a case-based survey study

Manon Kappelhof,1,2 Johanna Ospel,2,3 Nima Kashani ,2 Petra Cimflöva ,4 Nishita Singh,4 Mohammed A Almekhlafi ,5 Bijoy K Menon,4 Jens Fiehler ,5 Michael Chen ,6 Nobuyuki Sakai,7 Mayank Goyal ,2,4

ABSTRACT

Background Intravenous alteplase is currently the only evidence-based treatment for medium-vessel occlusion stroke (MeVO; M2/3, A2/3, and P2/3 vessel segment occlusions), but due to its limited efficacy, endovascular treatment (EVT) is increasingly performed in these patients. In this case-based survey study, we examined the influence of intravenous alteplase treatment on physicians’ decision-making for EVT in primary MeVO stroke.

Methods In an international web-based survey among physicians involved in acute stroke care, participants provided their EVT decision for six quasi-identical fictional MeVO case scenarios (three with and without intravenous alteplase administered). Each scenario showed radiological images and clinical information in the form of a short case vignette. We compared EVT decisions (“immediate EVT”, “no EVT”, or “wait for alteplase effect” [in case scenarios with alteplase treatment only]) for case scenarios with and without alteplase treatment. Clustered multivariable logistic regression was performed to assess the effect of alteplase on treatment decision.

Results The survey was completed by 366 physicians from 44 countries, resulting in 2196 responses included in this study. In alteplase-treated cases, 641/1098 (58.4%) responses favored immediate EVT, (279/1098 [25.4%]) favored no EVT and 178/1098 (16.2%) opted to wait for alteplase effect. In non-alteplase-treated case scenarios, 846/1098 (78.7%) were in favor of and 252/1098 (21.3%) against EVT. Intravenous alteplase was associated with a lower chance of a decision in favor of immediate EVT (adjusted OR 0.38 [95%CI 0.31 to 0.46]).

Conclusions Intravenous alteplase is an important factor in EVT decision-making for MeVO stroke. However, even in alteplase-treated patients, more than half of the physicians decided to proceed with EVT without waiting for alteplase effect.

INTRODUCTION

Intravenous alteplase followed by endovascular treatment (EVT) is the standard of care for acute ischemic stroke (AIS) due to large-vessel occlusion (LVO), in alteplase-eligible patients.1 With regard to AIS due to medium-vessel occlusion (MeVO), that is, M2/3, A2/3, and P2/3 occlusions, there is currently no randomized evidence proving the safety and efficacy of EVT. Thus, intravenous alteplase is the only treatment option with a level 1A guideline recommendation for MeVO patients, although many of them do not qualify for alteplase treatment due to their relatively mild symptoms (National Institutes of Health Stroke Scale (NIHSS) <6).1–4 However, alteplase efficacy in MeVO stroke is limited, with early complete recanalization following alteplase administration occurring in less than 50%.5 Given the overwhelming efficacy of EVT in LVO stroke6 and encouraging preliminary safety and efficacy data in the MeVO patient population,7 physicians are increasingly treating MeVO patients with EVT.8–10 A well-designed clinical trial to evaluate EVT in MeVO stroke is needed, but a logistical concern for such a trial includes understanding which factors may influence clinical equipoise for EVT. In this case-based survey study, we aimed to measure the degree of influence prior intravenous alteplase treatment would have on physicians’ EVT decision-making in MeVO stroke.

METHODS

The Conjoint Health Research Ethics Board of the University of Calgary approved this study (REB20-2086). An international, web-based, anonymous survey was conducted to explore current treatment practice and EVT decision-making in AIS due to MeVO among a broad, international audience of physicians involved in acute stroke care. Approximately 1400 stroke physicians of any specialty were invited to participate in the survey, based on their experience with EVT for AIS and their involvement in previous clinical trials on stroke. The online survey tool Qualtrics (Qualtrics.com) was used for survey distribution, data collection, encryption, and secure data storage. Access to the survey data was password-protected and granted to the study investigators only. Incomplete survey entries were excluded to avoid duplicate responses and incomplete data. Study data are available on reasonable request to the corresponding author.
Survey design
Participants were shown 33 MeVO stroke case scenarios, each consisting of a set of imaging findings and accompanying clinical information in the form of short case vignettes that included a fictional patient’s age, baseline NIHSS, baseline ASPECTS, occlusion location of a primary isolated MeVO, and in some cases CT-perfusion-based core and penumbra volumes. Case vignettes were constructed based on combined data from multiple clinical cases and fictional data, and do not represent real patients. Participants were then asked whether they would offer EVT to the patient or not (binary response: yes/no). In case the vignette indicated that the patient received intravenous alteplase, a third response option was provided (“wait for alteplase effect”). This study analyzes response data from six case-scenarios: three in which patients received intravenous alteplase, and three quasi-identical scenarios, the only difference being that the case vignette indicated that the patient was ineligible for intravenous alteplase (table 1). Corresponding anonymous imaging findings as they were provided to the survey respondents are shown in online supplemental figures 1-3.

Survey participants
Stroke physicians (neurologists, interventional neuroradiologists, neurologists, neurosurgeons, and other physicians directly involved in acute stroke care) were invited to participate in the survey, without restrictions for personal caseload, hospital setting, geographical location, experience, and level of training or career stage. Prior to answering the case scenarios, participants were asked to provide some basic information about their country of practice, years of experience in treating strokes, age range, specialty, and career stage.

Statistical analysis
Participants’ baseline characteristics were summarized using descriptive statistics appropriate to the type of data. EVT decisions overall, with and without intravenous alteplase treatment were calculated and compared between physician specialties, geographic regions, and by occlusion location. Multivariable logistic regression with respondent identity and scenario as cluster variables was performed to assess the independent effect of intravenous alteplase on the decision to treat with EVT. Changes in treatment decision between scenarios with and without intravenous alteplase treatment decision were visualized with Sankey diagrams. Data analyses were performed in Stata 16.1. Figures were created with Microsoft Excel, version 16.45 and Microsoft PowerBI, version 2.88.1682.0.

RESULTS
A total number of 356 physicians from 44 countries completed the survey, resulting in 2196 responses for the six fictional case scenarios included in this study (n=1098 for scenarios with and without intravenous alteplase treatment each). In total, 217 survey entries were incomplete and excluded. Details on participants’ demographics are shown in online supplemental table 1.

Intravenous alteplase and EVT decision
For case scenarios where intravenous alteplase was administered, 641/1098 (58.4%) responses were in favor of immediate EVT, and “no EVT” was the second most common answer (279/1098 responses [25.4%]), while only 178/1098 (16.2%) responses were in favor of waiting for intravenous alteplase effect, as shown in figure 1A. When the patient described in the scenario was not eligible for intravenous alteplase treatment before EVT, immediate EVT was favored by 846/1098 (78.7%), see figure 1B. When stratifying responses by occlusion site, decision

---

Table 1  Fictional case scenarios used in this study

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Occlusion site</th>
<th>Age</th>
<th>Sex</th>
<th>NIHSS</th>
<th>Onset to CT time</th>
<th>ASPECTS</th>
<th>CTP imaging findings</th>
<th>Intravenous alteplase</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>M2/3</td>
<td>86</td>
<td>Male</td>
<td>9</td>
<td>130 min</td>
<td>9</td>
<td>CTP core volume (rCBF &lt;30%) 7 mL CTP penumbra volume: not provided</td>
<td>Yes</td>
</tr>
<tr>
<td>1B</td>
<td>M2/3</td>
<td>86</td>
<td>Male</td>
<td>9</td>
<td>130 min</td>
<td>10</td>
<td>CTP core volume (rCBF &lt;30%) 7 mL CTP penumbra volume: not provided</td>
<td>Not eligible</td>
</tr>
<tr>
<td>2A</td>
<td>A3</td>
<td>79</td>
<td>Male</td>
<td>8</td>
<td>135 min</td>
<td>NA</td>
<td>CTP core volume (rCBF &lt;30%) 9 mL CTP penumbra volume (Tmax &gt;6) 30 mL</td>
<td>Yes</td>
</tr>
<tr>
<td>2B</td>
<td>A3</td>
<td>79</td>
<td>Male</td>
<td>8</td>
<td>135 min</td>
<td>NA</td>
<td>CTP core volume (rCBF &lt;30%) 7 mL CTP penumbra volume (Tmax &gt;6) 30 mL</td>
<td>Not eligible</td>
</tr>
<tr>
<td>3A</td>
<td>P2/3</td>
<td>52</td>
<td>Male</td>
<td>8</td>
<td>90 min</td>
<td>NA</td>
<td>CTP core volume (rCBF &lt;30%) 4 mL CTP penumbra volume (Tmax &gt;6) 24 mL</td>
<td>Yes</td>
</tr>
<tr>
<td>3B</td>
<td>P2/3</td>
<td>52</td>
<td>Male</td>
<td>8</td>
<td>90 min</td>
<td>NA</td>
<td>CTP core volume (rCBF &lt;30%) 4 mL CTP penumbra volume (Tmax &gt;6) 24 mL</td>
<td>Not eligible</td>
</tr>
</tbody>
</table>

* A3, third segment of the anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score for early ischemic changes on CT; CTP, CT perfusion; M2/3, second/third segment of the middle cerebral artery; NA, not applicable (ASPECTS only accounts for middle cerebral artery territory); P2/3, second/third segment of the posterior cerebral artery; rCBF, relative cerebral blood flow.
changes in EVT decision between scenarios with and without intravenous alteplase treatment. The vertical gray bar on the left represents the total number of responses. The vertical bars in the middle of the diagram show EVT decisions for alteplase-eligible case scenarios (either "immediate EVT", "no EVT", or "wait for alteplase effect"). Vertical bars on the right show EVT decisions for alteplase-ineligible case scenarios. The width of the streams is proportional to the number of responses. Note that respondents who initially decided to wait for alteplase effect mostly decided to proceed with EVT in alteplase-ineligible case scenarios. A3, anterior cerebral artery third segment; EVT, endovascular treatment; M2/3, middle cerebral artery second/third segment; P2/3, posterior cerebral artery second/third segment.

### DISCUSSION

In this study, intravenous alteplase treatment was significantly associated with decreased chances of a decision in favor of immediate EVT in MeVO stroke, but even in alteplase-eligible patients, the majority of physicians decided to proceed with EVT without waiting for an alteplase treatment effect. Decision rates in favor of immediate EVT were highest among junior physicians, physicians from Europe, and those trained in interventional neuroradiology and neurosurgery.

Previous studies report higher rates of early recanalization with a slight, although non-significant, improvement in clinical outcomes following MeVO stroke with intravenous alteplase administration. Our results clearly reflect this alteplase treatment effect, with significantly higher EVT decision rates in alteplase-eligible patients (79% vs 58%). Furthermore, one out of six physicians stated that they would wait to see whether the patient shows clinical improvement after alteplase before making a decision on EVT. However, probably owing to the rather small effect of alteplase on functional outcome in previous studies, more than half of the survey participants decided to immediately proceed with EVT even in patients who received intravenous alteplase. Out of those who decided to wait for an alteplase treatment effect, the vast majority opted for immediate EVT if alteplase was contraindicated.

However, all described patients in our survey had an NIHSS score of 8 or 9. Guidelines advise EVT in LVO strokes from NIHSS 6: strokes with less neurological deficits are often considered mild. For patients with mild strokes, which account for a relatively large proportion of MeVO patients due to the more distal occlusion location, intravenous alteplase was shown to improve functional independence rates, whereas an additional benefit of EVT in this patient group has not been proven. As such, more physicians might have preferred to wait for the effect of administered alteplase if patients had lower NIHSS scores. In addition, less severe neurologic deficits in MeVO stroke may affect patient triaging, in turn affecting workflow times and alteplase efficacy. In LVO strokes, the role of alteplase in patients presenting directly to an EVT-performing center seems
limited, since direct EVT and alteplase followed by EVT give very similar outcomes.21

Procedural complications of EVT may form a drawback for physicians treating MeVO strokes. Important complications after EVT include intracranial hemorrhage and vessel dissection.6 These risks may be increased in MeVO strokes, since the target vessels are smaller and more distally located. However, new techniques, smaller devices, and more flexible catheters specifically designed for distal thrombectomy have improved procedural safety.16-18

EVT decision rates in this study differed based on occlusion location. In scenarios with A2/3 occlusion, immediate EVT was favored only by 51% (alteplase-eligible patients)/71% (alteplase-ineligible patients) of respondents, while these numbers were much higher for scenarios with M2/3 occlusion (57%/83%) and P2/3 occlusion (82%/67%). The relatively high willingness to proceed with immediate EVT in P2/3 MeVOs could potentially reflect the lack of high-level evidence for IV thrombolysis in posterior circulation MeVOs,19 though one could argue that this applies to EVT as well. In fact, the safety and efficacy of EVT has not even been formally proven for LVOs in the posterior circulation,20 and there is complete paucity of high-level evidence on EVT for MeVOs in posterior circulation. The relatively young patient age (52 years), short onset to CT time (90 min), and small ischemic core volume (4 mL) in the posterior circulation occlusion scenario probably also influenced participants’ treatment decisions. The reason for the relatively low EVT decision rates in the scenarios with A3 occlusion remains unclear. They could be partly related to the fact that the deficits in isolated, more distal anterior cerebral artery occlusions can be relatively subtle and are often not well reflected in the NIHSS. It is however important to note that this impression is often deceptive: common sequelae of anterior cerebral artery strokes such as memory impairment, emotional lability, and isolated sensory deficits are often highly disabling, although they might not immediately become obvious in a focused neurological examination.21 The same applies to the validity of the NIHSS in PCA strokes: P2/P3 occlusions often present with lower NIHSS scores, possibly because the NIHSS does not optimally reflect the typical posterior circulation stroke symptoms.10 Therefore, we included detailed descriptions of the neurological loss of function for each case scenario, rather than only an NIHSS value (see online supplemental figures 1-3).

We observed an inverse relationship between physician experience and the willingness to proceed with immediate EVT, with physicians in training opting most often for immediate EVT, and board-certified physicians with >10 years of experience deciding least often in favor of immediate EVT. Furthermore, the “gap” between EVT decisions for alteplase-eligible and -ineligible scenarios decreased in less experienced physicians. This may indicate that younger physicians, having seen more of the rise and successes of EVT after the trials of 2015/2016,25 and less of the negative trials in the preceding years,21 have more positive expectations of EVT outcomes. For alteplase, the same effect may be true for physicians who saw the successes after the trials in the late 1990s.24,26

CONCLUSIONS

Intravenous alteplase treatment was an important factor in EVT decision-making for MeVO stroke in this study, but even in alteplase-eligible patients, more than half of the physicians decided to proceed with EVT immediately, without waiting for alteplase effect.
Ischemic stroke

Author affiliations

1 Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
2 Diagnostic Imaging, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
3 Radiology, University Hospital Basel, Basel, Switzerland
4 Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
5 Department of Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany
6 Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
7 Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

Twitter Nima Kashani @nimakashani, Mohammed A Almekhlafi @AlmekhlafiMaJens Fiehler @Fie0815 and Michael Chen @dr_mchen

Acknowledgements We would like to acknowledge all survey participants for their time and effort invested in answering the survey. We thank Moiz Hafeez for his contribution to the data entry of the survey scenarios.

Contributors Dr. Kappelhof and Dr. Ospel contributed equally. Dr. Kappelhof: substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data for the work, and drafting the work and revising it critically for important intellectual content, and final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Dr. Ospel: substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data for the work, and drafting the work and revising it critically for important intellectual content, and final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Dr. Goyal: substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data for the work, and drafting the work and revising it critically for important intellectual content, and final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Dr. Menon: substantial contributions to the conception of the work, the acquisition and interpretation of data for the work, and revising the work critically for important intellectual content, and final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Dr. Chen reports editorial board membership at Stroke (Assistant Editor), and he reports personal fees from Penumbra. Dr. Sakai reports personal fees from Penumbra, and he reports editorial board memberships at Journal of NeuroInterventional Surgery and Neuroradiology (Editor). Dr. Fiehler reports personal fees from Penumbra, personal fees from Microvention, Medtronic, personal fees from Codman, Cerenovus, Penumbra, Phenox, other (stock: ownership) from Tegus outside the submitted work; and editorial board memberships at World Journal of Radiology (Associate Editor) and Clinical Neuroradiology (Editor); and executive functions with University Medical Center Hamburg-Eppendorf, Eppdata GmbH. Dr. Menon reports personal fees from Medtronic outside the submitted work; and editorial board memberships at Journal of NeuroInterventional Surgery. Dr. Singh: substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data for the work, and revising the work critically for important intellectual content, and final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Dr. Saqqur: substantial contributions to the acquisition, analysis, and interpretation of data for the work, and revising the work critically for important intellectual content, and final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Dr. Goyal has a patent for systems of acute stroke diagnosis issued and licensed.

Patient consent for publication Not required.

Ethics approval The Conjoint Health Research Ethics Board of the University of Calgary approved this study (REB20-2086).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available from the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, and transform upon the work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/licenses/by/4.0/

ORCID iDs

Nima Kashani http://orcid.org/0000-0002-9752-784X
Petra Cimflíva http://orcid.org/0000-0001-8508-383X
Mohammed A Almekhlafi http://orcid.org/0000-0001-9550-8197
Jens Fiehler http://orcid.org/0000-0001-8533-7478
Michael Chen http://orcid.org/0000-0003-2412-8167
Mayank Goyal http://orcid.org/0000-0001-9060-2109

REFERENCES

Ischemic stroke

26 Group TI-3 collaborative group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet 2013;76:768–76.